Now I'd like to turn to our ongoing role in the pandemic response. The business also saw decentralized trials increasing by more than 50% versus prior year. Drug Development continues to recover with nearly 85% of sites now open. The trailing 12-month net book-to-bill for Drug Development remains strong at 1.34. Esoteric and routine testing demonstrated solid year-over-year growth for the quarter. In Diagnostics, we experienced broad geographic recovery in our Base Business and across our testing portfolio. We saw consistent recovery across both businesses. The Base Business for both Diagnostics and Drug Development performed well with 10% and 22% growth, respectively. Glenn will cover those in more detail in a few minutes.
#Laboratory corporation of america holdings full#
As a result of our strong performance and our improved outlook, we're raising full year guidance for revenue, adjusted EPS and free cash flow. Revenue totaled $4.1 billion, adjusted EPS reached $6.82, and free cash flow was $650 million. In the third quarter, we delivered strong results. At the same time, we've remained focused on helping the world through the pandemic. We serve as a trusted source of health information that helps customers advance healthcare and guide medical decisions. At Labcorp, we continue to leverage innovation, science and technology to accelerate our strategy as we work to improve health and improve lives around the world. Schechter - Chairman, President and Chief Executive Officer We have no obligation to provide any updates to these forward-looking statements even if our expectations change.Īdam H.
Some of these factors are set forth in detail in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and in the company's other filings with the SEC. These forward-looking statements include, but are not limited to, statements with respect to the estimated 2021 guidance and the related assumptions, the projected impact of various factors on the company's businesses, operating and financial results, cash flows and/or financial condition, including the COVID-19 pandemic and general economic and market conditions, our responses to the COVID-19 pandemic, future business strategies, expected savings and synergies and opportunities for future growth.Įach of the forward-looking statements is based upon current expectations and is subject to change based upon various factors, many of which are beyond our control, that could affect our financial results. Additionally, we are making forward-looking statements. This morning, in the Investor Relations section of our website at we posted both our press release and an Investor Relations presentation with additional information on our business and operations, which include a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call. With me today are Adam Schechter, Chairman and Chief Executive Officer and Glenn Eisenberg, Executive Vice President and Chief Financial Officer. As detailed in today's press release, there will be a replay of this conference call available via telephone and Internet. Good morning and welcome to Labcorp's Third Quarter 2021 Conference Call. It serves clients in more than 100 countries.Thank you, operator. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. The DD segment is a contract research organizations (CRO) business that provides end-to-end drug development services.
In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States.
The Dx segment is an independent clinical laboratory business. Its segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Laboratory Corporation of America Holdings is a global life sciences company.
0 kommentar(er)
